What the Promise of Genetic Therapies Means to Me

I felt unrelenting hope watching the first plenary of this year’s North American Cystic Fibrosis Conference. As I learned about progress that has been made in sickle cell disease, and how those learnings may help us develop a genetic therapy for CF, it showed me that the CF community is supporting people like me who can’t take modulators.

Nov. 2, 2023 | 3 min read
A light-skinned woman with light-colored hair
Ruby Steuart, MMS, PA-C
Ruby Steuart selfie with a face mask.

As one of the approximately 10% of people with cystic fibrosis who are ineligible for or can’t tolerate CFTR modulators, I was incredibly excited to envision our future through watching the North American CF Conference’s Plenary 1, presented by Drs. Thompson and McCray. Better yet, I was excited to envision the future of all CF patients because the potential gene therapies discussed take a mutation-agnostic approach, allowing the therapies to be used in all CF patients, regardless of mutation. 

The first portion of the plenary focused on sickle cell disease, a devastating disease affecting millions of people. Sickle cell disease has parallels with cystic fibrosis in its genetic basis. Both sickle cell disease and cystic fibrosis are autosomal recessive conditions that are caused by DNA mutations resulting in defective protein production. There are several genetic therapy clinical trials for sickle cell disease and another blood disorder called beta thalassemia. These treatment advances truly show the potential of genetic therapy in treating so many conditions — including CF! 

Cystic fibrosis had no known treatments in 1938, when Dr. Dorothy Andersen first characterized CF. It wasn’t until 1989 that the CFTR gene was discovered. Fast forward to today — now we are exploring the many ways that we can correct that gene and restore function to the CFTR protein. 

According to Dr. McCray, genetic therapies may be pursued for cystic fibrosis through gene addition, adenine base editing, and super-exon insertion.

While I’d love nothing more than to dive into the scientific details, I’ll sum it up into one key takeaway: every aspect of genetic therapy for cystic fibrosis patients is being researched.
 

Researchers are laser-focused on effective delivery methods, airway anatomy, key CFTR expressing cells, viral and non-viral delivery vectors, and so much more. As a physician assistant, I see a future of advancing medical treatments and incredible research potential. But more importantly, as a patient, I see the ongoing fulfillment of the promise that the CF community made — to keep going until 100% of us have a treatment.

Since Trikafta® was approved in October 2019, I have maintained hope in that promise that the CF community and CF Foundation made to us. I have participated in research studies and clinical trials since I was a child with the hope that my dedication, coupled with the dedication of the entire CF community, will result in a cure. The 2023 NACFC Plenary 1 is confirmation that there is significant momentum in genetic therapies being developed. There are many challenges still ahead, but this proof is the basis for my unrelenting hope that one day CF will stand for Cure Found.

During plenary 1 of our North American Cystic Fibrosis Conference, Paul McCray, Jr., MD, and Alexis Thompson, MD, share how we can gain valuable insights from the development of genetic therapies for other diseases and apply these approaches to cystic fibrosis.

Interested in sharing your story? The CF Community Blog wants to hear from you.

This site contains general information about cystic fibrosis, as well as personal insight from the CF community. Opinions and experiences shared by members of our community, including but not limited to people with CF and their families, belong solely to the blog post author and do not represent those of the Cystic Fibrosis Foundation, unless explicitly stated. In addition, the site is not intended as a substitute for treatment advice from a medical professional. Consult your doctor before making any changes to your treatment.

Share this article
Topics
Genetic Therapies | North American CF Conference | Research
A light-skinned woman with light-colored hair

Ruby was born and raised in Southern Maryland, where she currently resides and works as an Emergency Medicine Physician Assistant — a career that was inspired by her fight against cystic fibrosis. She was diagnosed with CF at 18 months old and is one of the approximately 2.7% of people with CF with two nonsense mutations. She loves to read, play piano, and work out in her spare time. Ruby is a Maryland CF Foundation Ambassador and has been the team leader of her Annapolis Great Strides team, Team Fireworks, since 2014. You can find Ruby on Instagram.

Recent Community Posts
Cycling Across America
Blog | 5 min read
Reflecting on 50 Years of Volunteering
Blog | 5 min read
How My Brother Inspired Me to Give Back
Blog | 7 min read